Antiangiogenic therapy in colorectal cancer

Kabir Mody, Candice Baldeo, Tanios Bekaii-Saab

Research output: Contribution to journalReview articlepeer-review

23 Scopus citations


Colorectal carcinoma is the third most common cancer worldwide. Approximately 20% of patients with colorectal cancer will have metastatic disease at the time of initial diagnosis, and approximately 30% to 50% of patients with primary colon cancer will relapse and die of metastatic cancer. The 5-year survival rate of metastatic colorectal cancer remains disappointing at approximately 10%. Angiogenesis plays a significant role in tumor growth and metastasis in colorectal carcinoma. There are currently 4 US Food and Drug Administration-approved antiangiogenic agents for metastatic colorectal cancer. Bevacizumab is the only antiangiogenic agent approved by the US Food and Drug Administration for first-line treatment of metastatic colorectal cancer. Other antiangiogenic agents include ramucirumab, ziv-aflibercept, and regorafenib. We review the data supporting the use of antiangiogenics in this disease.

Original languageEnglish (US)
Pages (from-to)165-170
Number of pages6
JournalCancer Journal (United States)
Issue number4
StatePublished - 2018


  • Bevacizumab
  • Cancer
  • Colon
  • Rectum
  • VEGF

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Antiangiogenic therapy in colorectal cancer'. Together they form a unique fingerprint.

Cite this